Blood and immunity

• EBV-associated hemophagocytic lymphohistiocytosis
  10 May 2011, by admin

  Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis

• Philadelphia chromosome-positive acute lymphoblastic leukemia
  17 March 2011

  See also
  acute lymphoblastic leukemia (ALL)
  References
  A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Zuo Z, Jones D, Yao H, Thomas DA, O’Brien S, Ravandi F, Kantarjian HM, Abruzzo LV, Medeiros LJ, Chen SS, Luthra R. Mod Pathol. 2010 Nov;23(11):1524-34. PMID: #20729815# (...)

• neonatal leukemia
  20 January 2011

  See also
  neonatal transient myeloproliferative disorder trisomy 21-associated neonatal transient myeloproliferative disorder
  neonatal hemochromatosis

• primary immunodeficiency-associated lymphoproliferative diseases
  23 December 2010

  PIALPDs
  Lymphoproliferative disorders (LPDs) are a severe complication in primary immunodeficiency and post-transplant patients. In primary immunodeficiency patients, LPDs are not well-known.
  PIALPDs are frequently extranodal, EBV-associated, and are more commonly pleomorphic in primary immunodeficiency than in post-transplant patients.
  A low T-cell count and abnormal T-cell function indicate bad prognosis.
  Polymorphic LPDs (PLPDs) are most frequent, whereas lymphomas are rare, and (...)

• IgA plasmacytoma
  30 November 2010

  plasmacytomas expressing immunoglobulin A

• trisomy 21-associated acute myeloid leukemia
  9 November 2010

  Children with Down syndrome (DS) have an approximately 50-fold increased risk of developing AML in the first 5 years of life, as compared to those without DS.
  About 1-2% of children with DS develop AML, with the great majority being megakaryoblastic. In contrast, this morphological variant of AML is very rare (about 5% of AML) in children of corresponding age without DS.
  DS-associated AML develops predominantly in the first 3 years of life. In most cases it occurs de novo but is (...)

• trisomy 21-associated myeloid proliferations
  9 November 2010

  Myeloid proliferations related to Down syndrome

• trisomy-21 associated transient abnormal myelopoiesis
  9 November 2010

  trisomy 21-associated TAM; Down syndrome-associated TAM;

• neonatal transient myeloproliferative disorder
  9 November 2010

  perinatal leukemoid reaction

• trisomy 21-associated neonatal transient myeloproliferative disorder
  9 November 2010

  Approximately 10% of DS newborns present with a hematological disorder known as "transient abnormal myelopoiesis" (TAM).
  Genetic alterations (presence of GATA1 mutations) and morphological and laboratory findings may be the same as typical trisomy 21-associated AML.
  In 70-80% of cases, TAM resolves spontaneously over a period of several weeks to 3 months, whilst in the remaining cases a non-transient acute myeloid leukemia, usually of megakaryoblastic type, develops 1 to 3 years later. (...)

0 | ... | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90 | 100 | ... | 270